Yeji

$CABA

Cabaletta Bio, Inc.

Runway:8 mo
NasdaqMarket cap: —CIK 0001759138

Upcoming catalysts

1 surfaced
NDA/BLA filedDate TBD~ low confidence
$CABACabaletta Bio, Inc.
“If successful, data from this cohort will support Cabaletta's first projected Biologics License Application (BLA) submission for rese-cel in myositis next year.”

Drug pipeline

CABA-201
Relapsing Multiple Sclerosis (RMS)
DSG3-CAART
Pemphigus Vulgaris
MuSK-CAART
MuSK Myasthenia Gravis
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Idiopathic Inflammatory Myopathy

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06121297CABA-201Phase 2Recruiting2029-12-01
NCT06359041CABA-201Phase 2Active Not Recruiting2029-09-01
NCT06328777CABA-201Phase 2Recruiting2029-07-01
NCT04422912DSG3-CAARTPhase 2Recruiting2029-01-01
NCT07006805CABA-201Phase 2Not Yet Recruiting2028-09-01
NCT06154252CABA-201 following preconditioning with fludarabine and cyclophosphamidePhase 3Recruiting2028-07-01
NCT05451212MuSK-CAARTPhase 1Completed2025-07-24